AAAAAA

   
Results: 1-24 |
Results: 24
Clinical relevance of biologic factors in male breast cancer
Authors: Meijer-van Gelder, ME Look, MP Bolt-de Vries, J Peters, HA Klijn, JGM Foekens, JA
Citation: Me. Meijer-van Gelder et al., Clinical relevance of biologic factors in male breast cancer, BREAST CANC, 68(3), 2001, pp. 249-260
Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviraltherapy
Authors: Look, MP Riezler, R Berthold, HK Stabler, SP Schliefer, K Allen, RH Sauerbruch, T Rockstroh, JK
Citation: Mp. Look et al., Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviraltherapy, METABOLISM, 50(11), 2001, pp. 1275-1281
Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy
Authors: Foekens, JA Romain, S Look, MP Martin, PM Klijn, JGM
Citation: Ja. Foekens et al., Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy, CANCER RES, 61(4), 2001, pp. 1421-1425
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
Authors: Foekens, JA Peters, HA Grebenchtchikov, N Look, MP Meijer-van Gelder, ME Geurts-Moespot, A van der Kwast, TH Sweep, CGJ Klijn, JGM
Citation: Ja. Foekens et al., High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer, CANCER RES, 61(14), 2001, pp. 5407-5414
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
Authors: Schuyer, M van der Burg, MEL Henzen-Logmans, SC Fieret, JH Klijn, JGM Look, MP Foekens, JA Stoter, G Berns, EMJJ
Citation: M. Schuyer et al., Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2, BR J CANC, 85(9), 2001, pp. 1359-1367
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
Authors: de Witte, JH Foekens, JA Brunner, N Heuvel, JJTM van Tienoven, TH Look, MP Klijn, JGM Geurts-Moespot, A Grebenchtchikov, N Benraad, TJ Sweep, CGJ
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours, BR J CANC, 85(1), 2001, pp. 85-92
Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment
Authors: van der Flier, S Brinkman, A Look, MP Kok, EM Meijer-van Gelder, ME Klijn, JGM Dorssers, LCJ Foekens, JA
Citation: S. Van Der Flier et al., Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment, J NAT CANC, 92(2), 2000, pp. 120-127
The urokinase-type plasminogen activator system in resected non-small-celllung cancer
Authors: Salden, M Splinter, TAW Peters, HA Look, MP Timmermans, M van Meerbeeck, JPAM Foekens, JA
Citation: M. Salden et al., The urokinase-type plasminogen activator system in resected non-small-celllung cancer, ANN ONCOL, 11(3), 2000, pp. 327-332
Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosisfactor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease
Authors: Look, MP Altfeld, M Kreuzer, KA Riezler, R Stabler, SP Allen, RH Sauerbruch, T Rockstroh, JK
Citation: Mp. Look et al., Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosisfactor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease, AIDS RES H, 16(13), 2000, pp. 1215-1221
Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients
Authors: Look, MP
Citation: Mp. Look, Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients, INT J B MAR, 15(1), 2000, pp. 70-72
Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-cystathionase?
Authors: Look, MP Riezler, R Reichel, C Brensing, KA Rockstroh, JK Stabler, SP Spengler, U Berthold, HK Sauerbruch, T
Citation: Mp. Look et al., Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-cystathionase?, SC J GASTR, 35(8), 2000, pp. 866-872
Elevated soluble tumour necrosis factor receptor serum concentrations and short-term mortality in liver cirrhosis without acute infections
Authors: Reichel, C Sudhop, T Braun, B Kreuzer, KA Hahn, C Look, MP von Bergmann, K Sauerbruch, T Spengler, U
Citation: C. Reichel et al., Elevated soluble tumour necrosis factor receptor serum concentrations and short-term mortality in liver cirrhosis without acute infections, DIGESTION, 62(1), 2000, pp. 44-51
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
Authors: Berns, EMJJ Foekens, JA Vossen, R Look, MP Devilee, P Henzen-Logmans, SC van Staveren, IL van Putten, WLJ Inganas, M Meijer-van Gelder, ME Cornelisse, C Claassen, CJC Portengen, H Bakker, B Klijn, JGM
Citation: Emjj. Berns et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, CANCER RES, 60(8), 2000, pp. 2155-2162
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
Authors: Foekens, JA Peters, HA Look, MP Portengen, H Schmitt, M Kramer, MD Brunner, N Janicke, F Meijer-van Gelder, ME Henzen-Logmans, SC van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, CANCER RES, 60(3), 2000, pp. 636-643
Clinical relevance of the urokinase plasminogen activator system in breastcancer
Authors: Look, MP Foekens, JA
Citation: Mp. Look et Ja. Foekens, Clinical relevance of the urokinase plasminogen activator system in breastcancer, APMIS, 107(1), 1999, pp. 150-159
Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse
Authors: Meijer-van Gelder, ME Look, MP Bolt-de Vries, J Peters, HA Klijn, JGM Foekens, JA
Citation: Me. Meijer-van Gelder et al., Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse, J CL ONCOL, 17(5), 1999, pp. 1449-1457
Genetic alterations in ovarian borderline tumours and ovarian carcinomas
Authors: Schuyer, M Henzen-Logmans, SC van der Burg, MEL Fieret, JH Derksen, C Look, MP Meijer-van Gelder, ME Klijn, JGM Foekens, JA Berns, EMJJ
Citation: M. Schuyer et al., Genetic alterations in ovarian borderline tumours and ovarian carcinomas, EUR J OB GY, 82(2), 1999, pp. 147-150
Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial
Authors: Look, MP Gerard, A Rao, GS Sudhop, T Fischer, HP Sauerbruch, T Spengler, U
Citation: Mp. Look et al., Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial, ANTIVIR RES, 43(2), 1999, pp. 113-122
Vitamin E status in patients with liver cirrhosis: Normal or deficient?
Authors: Look, MP Reichel, C von Falkenhausen, M Hahn, C Stockinger, K von Bergmann, K Rao, GS Spengler, U Sauerbruch, T
Citation: Mp. Look et al., Vitamin E status in patients with liver cirrhosis: Normal or deficient?, METABOLISM, 48(1), 1999, pp. 86-91
Prognostic value of CD44 variant expression in primary breast cancer
Authors: Foekens, JA Dall, P Klijn, JGM Skroch-Angel, P Claassen, CJC Look, MP Ponta, H Van Putten, WLJ Herrlich, P Henzen-Logmans, SC
Citation: Ja. Foekens et al., Prognostic value of CD44 variant expression in primary breast cancer, INT J CANC, 84(3), 1999, pp. 209-215
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
Authors: de Witte, JH Sweep, CGJ Klijn, JGM Grebenschikov, N Peters, HA Look, MP van Tienoven, TH Heuvel, JJTM Vries, JBD Benraad, TJ Foekens, JA
Citation: Jh. De Witte et al., Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer, BR J CANC, 80(1-2), 1999, pp. 286-294
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
Authors: de Witte, JH Sweep, CGJ Klijn, JGM Grebenschikov, N Peters, HA Look, MP van Tienoven, TH Heuvel, JJTM van Putten, WLJ Benraad, TJ Foekens, JA
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients, BR J CANC, 79(7-8), 1999, pp. 1190-1198
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Authors: Foekens, JA Diamandis, EP Yu, H Look, MP Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer, BR J CANC, 79(5-6), 1999, pp. 888-894
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients
Authors: Foekens, JA Look, MP Bolt-de Vries, J Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients, BR J CANC, 79(2), 1999, pp. 300-307
Risultati: 1-24 |